{
    "eid": "2-s2.0-85030719959",
    "title": "Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease",
    "cover-date": "2017-12-01",
    "subject-areas": [
        {
            "$": "Drug Discovery",
            "@code": "3002"
        },
        {
            "$": "Pharmacology",
            "@code": "3004"
        }
    ],
    "keywords": [],
    "authors": [
        "Sang Hyoung Park"
    ],
    "citedby-count": 13,
    "ref-count": 52,
    "ref-list": [
        "Surgery in a population-based cohort of crohn's disease from Olmsted County, Minnesota (19702004)",
        "Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis",
        "Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort",
        "Converging goals of treatment of inflammatory bowel disease from clinical trials and practice",
        "Ustekinumab as induction and maintenance therapy for Crohn's disease",
        "Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study",
        "Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study",
        "A phase 2 study of Tofacitinib, an oral janus kinase inhibitor, inpatients with crohn's disease",
        "Tofacitinib for induction and maintenance therapy of Crohn's disease: Results of two phase IIb randomised placebo-controlled trials",
        "Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial",
        "Gastroenterology",
        "Mongersen, an oral SMAD7 antisense oligonucleotide, and crohn's disease",
        "Oral SMAD7 antisense drug for crohn's disease",
        "Gastroentrology",
        "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis",
        "Tofacitinib as induction and maintenance therapy for ulcerative colitis",
        "Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial",
        "Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial",
        "Ozanimod induction and maintenance treatment for ulcerative colitis",
        "Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis",
        "Early combined immunosuppression for the management of Crohn's disease (REACT): A cluster randomised controlled trial",
        "Gastroenterology",
        "Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease",
        "Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target",
        "Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease",
        "Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases",
        "Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn's Disease",
        "Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis",
        "Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease",
        "Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease",
        "Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors",
        "Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease",
        "Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis",
        "Vedolizumab as induction and maintenance therapy for Crohn's disease",
        "Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease",
        "Infliximab Trough Levels at Induction to Predict Treatment Failure during Maintenance",
        "Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease",
        "Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease",
        "Drug level-based anti-tumor necrosis factor therapy: Ready for prime time?",
        "Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta-analysis",
        "The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab",
        "Gut",
        "A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays",
        "Current status of biosimilars in the treatment of inflammatory bowel diseases",
        "The state of the art in the development of biosimilars",
        "A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study",
        "Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-\u03b1 agent (infliximab), in inflammatory bowel diseases",
        "Gastroenterology",
        "Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial",
        "Gastroenterology"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Seoul",
            "affilname": "University of Ulsan College of Medicine",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Rochester",
            "affilname": "Mayo Clinic",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}